Wealth Enhancement Advisory Services LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Wealth Enhancement Advisory Services LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 64.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 409,703 shares of the company's stock after purchasing an additional 160,826 shares during the quarter. Wealth Enhancement Advisory Services LLC owned approximately 0.09% of Zoetis worth $66,753,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. LPL Financial LLC grew its position in shares of Zoetis by 2.9% during the 2nd quarter. LPL Financial LLC now owns 341,259 shares of the company's stock valued at $59,161,000 after acquiring an additional 9,476 shares during the period. American Century Companies Inc. raised its stake in shares of Zoetis by 5.8% in the second quarter. American Century Companies Inc. now owns 899,935 shares of the company's stock valued at $156,013,000 after buying an additional 49,232 shares during the period. Meeder Asset Management Inc. lifted its position in shares of Zoetis by 175.3% during the 2nd quarter. Meeder Asset Management Inc. now owns 31,170 shares of the company's stock valued at $5,404,000 after buying an additional 19,846 shares during the last quarter. Meeder Advisory Services Inc. lifted its position in shares of Zoetis by 21.7% during the 2nd quarter. Meeder Advisory Services Inc. now owns 9,529 shares of the company's stock valued at $1,652,000 after buying an additional 1,698 shares during the last quarter. Finally, Prevail Innovative Wealth Advisors LLC grew its stake in shares of Zoetis by 40.1% during the 2nd quarter. Prevail Innovative Wealth Advisors LLC now owns 26,592 shares of the company's stock worth $4,610,000 after acquiring an additional 7,615 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 1.0 %

Zoetis stock traded down $1.72 during trading hours on Friday, reaching $163.30. The stock had a trading volume of 3,179,470 shares, compared to its average volume of 2,470,128. The company has a fifty day simple moving average of $171.71 and a 200-day simple moving average of $180.23. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The stock has a market cap of $73.68 billion, a PE ratio of 30.70, a PEG ratio of 2.91 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the business earned $1.36 EPS. Zoetis's revenue was up 11.6% compared to the same quarter last year. Analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.22%. This is a boost from Zoetis's previous quarterly dividend of $0.43. Zoetis's payout ratio is 37.59%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of research reports. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday. Finally, UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective for the company. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.